Atlas Venture

growth-positive

Atlas Venture, a Massachusetts-based venture capital firm, has announced a new $450 million fund aimed at supporting innovative biotech companies. This is the firms fourteenth fund, matching the amount of its previous fund from March 2022. Over the past two years, Atlas has launched 16 new biotech companies and recruited around 100 executive leaders. The firm has been involved in significant acquisitions, including Eli Lillys acquisition of Versanis Bio and GSKs $1 billion purchase of Aiolos Bio. Several Atlas-backed companies, such as Disc Medicine and Korro Bio, have gone public. The most recent company to emerge from Atlass portfolio is Trace Neuroscience, which launched in November with $101 million in series A funding. The biotech investment sector has seen substantial activity, with other firms like Bain Capital Life Sciences and Arch Venture Partners also raising significant funds.